Janumet Xr is an anti-diabetic drug owned by Merck Sharp Dohme. It contains Metformin Hydrochloride and Sitagliptin Phosphate. The drug was first authorized for market use on February 2, 2012, and it's available in tablet, extended-release oral dosage forms. It has a total of 6 patents, of which 4 have already expired.
The generic versions of Janumet Xr are expected to be released after May 24, 2027. The last patent to expire will be US7326708*, titled 'Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor', on this date. The release of Janumet Xr generic is anticipated post this patent's expiry.
Janumet Xr is used for treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hydrochloride extended-release is appropriate. Its active ingredients, Metformin Hydrochloride and Sitagliptin Phosphate, contribute to its effectiveness.
Janumet Xr holds a total of 6 patents. 4 of these patents have already expired. The last patent, US7326708*, which discusses a 'Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor', is expected to expire on May 24, 2027. The availability of Janumet Xr generic hinges on this date. Below are the details of the patent: